Treatment with the LHRH agonists fulvestrant and palbociclib gradually decreased the levels of carcinoembryonic antigen (CEA) and CA15-3 tumor markers and magnetic resonance imaging (MRI) showed shrinkage of the tumor (Figure 4). Here, CEACAM5 is linked to neoplasm.